Cullen/Frost Bankers, Inc. Novavax Inc Transaction History
Cullen/Frost Bankers, Inc.
- $6.83 Billion
- Q2 2024
Shares
1 transactions
Others Institutions Holding NVAX
# of Institutions
284Shares Held
84.8MCall Options Held
5.43MPut Options Held
9M-
Vanguard Group Inc Valley Forge, PA14.1MShares$132 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.8MShares$111 Million0.0% of portfolio
-
Shah Capital Management9.82MShares$91.8 Million40.63% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY6.32MShares$59.1 Million0.08% of portfolio
-
State Street Corp Boston, MA6.07MShares$56.7 Million0.0% of portfolio
About NOVAVAX INC
- Ticker NVAX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,215,104
- Market Cap $731M
- Description
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...